BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

1 month ago 3

• Healthcare
• M&A

Sundry Photography/iStock Editorial via Getty Images

BioMarin Pharmaceutical (NASDAQ:BMRN) on Friday agreed to acquire Inozyme Pharma (NASDAQ:INZY), a developer of enzyme therapies, for $4.00 per share, or a total consideration of roughly $270M in an all-cash transaction.

The director boards of both companies have approved the

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal